Menu
Back to Journals » Cancer Management and Research » Volume 12
Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend
Authors Zhang J, Wen L, Zhou Q, He K, Teng L
Received 29 May 2020
Accepted for publication 19 August 2020
Published 16 September 2020 Volume 2020:12 Pages 8545—8554
DOI https://doi.org/10.2147/CMAR.S264032
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Chien-Feng Li
Jing Zhang, Liping Wen, Quan Zhou, Kuifeng He, Lisong Teng
Department of Surgical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China
Correspondence: Lisong Teng
Department of Surgical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003, People’s Republic of China
Tel/ Fax +86-571-87236881
Email lsteng@zju.edu.cn
Abstract: Gastric cancer (GC) is a cancer with high prevalence, and is one of the leading causes of cancer death worldwide. Metformin is a widely used hypoglycemic agent for type-2 diabetes mellitus (T2DM). Recently, metformin has drawn increasing attention in the field of cancer research for its emerging anti-cancer roles. However, the efficacy and underlying molecular mechanisms of metformin in the prevention and treatment for GC remain controversial. This review summarized the present clinical and mechanistic studies that investigated the efficacy of metformin in GC. It was found that the majority of clinical studies affirmed protective roles of metformin in both gastric cancer risk and survival rate. In addition, metformin’s effects in the prevention and treatment for GC involve multiple pathways mainly via AMPK and IGF-1R. It was concluded that metformin presents a unique opportunity for application against GC, but further clinical and mechanistic investigations are required to solidify the roles of metformin in GC.
Keywords: gastric cancer, metformin, AMPK, anti-tumor
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.